Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
225Ac-NM600
- Development stage
- Preclinical
- Lead developer
- Archeus Technologies
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
225Ac-NM600 is an investigational targeted alpha-particle therapy (TAT) composed of the alpha-emitting radioisotope actinium-225 conjugated to NM600, a small-molecule alkylphosphocholine (APC) analog. NM600 serves as a tumor-targeting vector by selectively binding to phospholipid ethers that are overexpressed in the plasma membranes of a wide variety of cancer cells and within the tumor microenvironment. Upon binding, the actinium-225 isotope releases high-energy alpha particles with a short path length (50-100 μm), inducing complex, lethal double-strand DNA breaks in the target tumor cells while minimizing collateral damage to adjacent healthy tissues. This approach is designed to treat both primary macroscopic tumors and disseminated microscopic metastatic disease. 225Ac-NM600 is being explored for the treatment of advanced solid tumors, particularly in combination with immune checkpoint inhibitors to overcome therapeutic resistance and promote a robust anti-tumor immune response.
- Other names
- actinium-225 NM600actinium225 NM600actinium 225 NM600[225Ac]Ac-NM600
02
Targets
DNA
Beyond the preview
Go deeper on 225Ac-NM600.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 225Ac-NM600.